Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ATR
ATR logo

ATR Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
125.700
Open
124.590
VWAP
125.23
Vol
52.73K
Mkt Cap
8.04B
Low
124.590
Amount
6.60M
EV/EBITDA(TTM)
11.30
Total Shares
63.77M
EV
9.15B
EV/OCF(TTM)
16.06
P/S(TTM)
2.23
AptarGroup, Inc. is engaged in designing and manufacturing of drug and consumer product dosing, dispensing and protection technologies. The Company serves various end markets, including pharmaceutical, beauty, food, beverage, personal care and home care. It operates in three segments. The Aptar Pharma segment sells proprietary dispensing systems, drug delivery systems, sealing solutions and services for the prescription drug, consumer health care, injectables, active material science solutions and digital health market. It also specializes in nasal drug delivery for delivering drugs. The Aptar Beauty segment sells dispensing systems and sealing solutions for the beauty, personal care and home care markets. The Aptar Closures segment sells dispensing systems, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and healthcare markets. This segment also includes the food protection business and the elastomeric flow-control technology business.
Show More

Events Timeline

(ET)
2026-03-19
17:10:00
AptarGroup Collaborates with ENA Respiratory on INNA 051 Clinical Study
select
2026-03-17 (ET)
2026-03-17
17:10:00
AptarGroup Appoints Gael Touya as New CEO
select
2026-02-05 (ET)
2026-02-05
17:10:00
Aptar Reports Q4 Revenue of $962.74M, Beating Consensus
select
2026-02-05
17:10:00
Aptar Sees FY26 Capital Expenditures of $260M-$280M
select

News

CNBC
4.0
03-20CNBC
Key Wall Street Rating Updates on Friday
  • Nvidia Rating Reaffirmed: Wolfe maintains Nvidia as an outperform, stating that with the stock priced at just 13x their bull case EPS, it is too cheap to ignore, potentially attracting more investor interest.
  • Arm Upgrade: HSBC upgrades Arm from reduce to buy, highlighting its strong positioning in the AI sector, suggesting that its transition to a major AI server CPU player presents a significant undervaluation opportunity for investors.
  • Apple App Store Revenue Slowdown: Morgan Stanley reiterates Apple as overweight, noting that App Store revenue growth decelerated to 6% YoY in Q1 2023, falling short of the expected 8%, indicating market caution regarding Apple's future growth prospects.
  • Oneok Upgrade: Jefferies upgrades Oneok from hold to buy, citing tangible upside potential in the current market environment, particularly as geopolitical tensions in the Middle East raise crude oil price risks.
Newsfilter
7.5
03-19Newsfilter
Aptar Pharma Supports Development of Next-Gen Nasal Spray
  • Clinical Study Progress: Aptar Pharma's UDS Powder Nasal Spray System is being utilized in ENA Respiratory's Phase II clinical study of INNA-051, aimed at evaluating its potential to protect against symptomatic viral respiratory infections, marking a significant innovation effort in respiratory health.
  • Technical Advantages: The UDS system is designed to deliver a single, precise dose of dry powder, ensuring consistent performance in clinical development settings, thereby enhancing drug reliability and patient experience, which is crucial for market competitiveness.
  • Moisture Protection: The nasal delivery system features Aptar CSP Technologies' innovative container closure system, incorporating 3-Phase Activ-Polymer™ technology to effectively protect the powder formulation from moisture, ensuring stability and efficacy to meet market demands for high-quality drug delivery.
  • Strategic Collaboration: The partnership between Aptar Pharma and ENA Respiratory not only showcases its leadership in drug delivery technologies but also reflects the company's strategic direction towards developing non-vaccine approaches to address respiratory diseases, further solidifying its influence in the pharmaceutical industry.
Newsfilter
5.0
03-17Newsfilter
AptarGroup Appoints Gael Touya as New CEO Effective September 2026
  • Leadership Transition: AptarGroup has announced that Gael Touya will succeed Stephan B. Tanda as CEO effective September 1, 2026, with Tanda remaining as an advisor to ensure a smooth transition, highlighting the company's focus on future growth.
  • Strategic Growth: With over 30 years at Aptar, Gael has driven 82% revenue growth as President of Aptar Pharma, showcasing his leadership in drug delivery, and will continue to expand strategies in consumer markets.
  • Operational Efficiency: Under Gael's leadership, Aptar Pharma has integrated technologies and services to enhance customer efficiency from early development to commercialization, strengthening the company's competitive position in the global drug delivery market.
  • Sustainability Commitment: During Stephan's tenure, Aptar's adjusted EBITDA margins increased from 19% in 2017 to 22% in 2025, alongside significant advancements in sustainability, reflecting the company's commitment to environmental responsibility.
seekingalpha
5.0
03-17seekingalpha
AptarGroup Appoints New CEO Gael Touya
  • Executive Change: AptarGroup announced that Gael Touya will become president and CEO effective September 1, 2026, succeeding Stephan B. Tanda, who has held the position since 2017, indicating a significant leadership shift for the company.
  • Transition Support: Stephan B. Tanda will continue to work as an advisor until the end of the year to ensure a smooth transition for new CEO Gael Touya, helping the company maintain stability as it enters its next growth phase.
  • Board Appointment: On the same day Gael Touya assumes his role, he will also be appointed as a director by the board, further solidifying his leadership position within the company and reflecting confidence in his future direction.
  • Retirement Plans: Stephan B. Tanda intends to retire from the board by the end of 2026, suggesting a shift in leadership style and strategic direction that could impact the company's long-term growth and market performance.
Newsfilter
9.0
03-16Newsfilter
Aptar Supports LTR Pharma's Intranasal Therapy Development
  • Clinical Study Progress: AptarGroup's nasal delivery system is utilized in LTR Pharma's Phase II clinical study of SPONTAN®, reflecting the company's ongoing commitment to supporting intranasal drug delivery technologies, which is expected to drive the development of innovative therapies.
  • First Patient Dosing: LTR Pharma recently announced the dosing of the first patients in the SPONTAN® study, which evaluates the safety and tolerability of the rapid-acting intranasal spray, further advancing clinical development and regulatory pathways.
  • Strengthened Technical Collaboration: Aptar's nasal spray platform is a multidose delivery system designed to provide accurate and consistent dosing of prescription drugs, enhancing Aptar's position as a trusted partner in advancing complex intranasal therapies through robust regulatory and technical expertise.
  • Strategic Investment Value: LTR Pharma's Executive Chairman noted that partnering with Aptar provides a solid foundation for their clinical and regulatory pathway, emphasizing the critical role of reliable nasal drug delivery in their development strategy, which may enhance market competitiveness.
Benzinga
2.0
03-02Benzinga
Energy Stocks Flash Momentum Warning for Investors
  • Momentum Indicator Warning: As of March 2, 2026, two stocks in the energy sector are signaling momentum warnings, particularly with Relative Strength Index (RSI) values exceeding 70, indicating potential overbought conditions that investors should heed.
  • Nordic American Tankers Performance: Nordic American Tankers (NYSE:NAT) reported disappointing quarterly results on February 26, and despite a 37% stock price increase over the past month, its RSI stands at 93.8, suggesting a risk of correction due to overvaluation.
  • Price Action Analysis: NAT's shares rose 6.1% to close at $5.73 on Friday, showing strong short-term performance; however, the high RSI indicates potential price adjustments ahead, prompting investors to monitor market developments closely.
  • Tsakos Energy Navigation Overview: Tsakos Energy Navigation (NYSE:TEN) is also under scrutiny, with strong momentum scores, although specific data is not disclosed, investors should consider overall market trends and individual stock performance.
Wall Street analysts forecast ATR stock price to rise
4 Analyst Rating
Wall Street analysts forecast ATR stock price to rise
1 Buy
3 Hold
0 Sell
Hold
Current: 0.000
sliders
Low
133.00
Averages
145.33
High
156.00
Current: 0.000
sliders
Low
133.00
Averages
145.33
High
156.00
BofA
George Staphos
Neutral
maintain
$147 -> $145
AI Analysis
2026-04-06
New
Reason
BofA
George Staphos
Price Target
$147 -> $145
AI Analysis
2026-04-06
New
maintain
Neutral
Reason
BofA analyst George Staphos lowered the firm's price target on AptarGroup to $145 from $147 and keeps a Neutral rating on the shares as part of the firm's preview for the packaging and paper group.
Wells Fargo
Equal Weight -> Overweight
upgrade
$133 -> $144
2026-03-20
Reason
Wells Fargo
Price Target
$133 -> $144
2026-03-20
upgrade
Equal Weight -> Overweight
Reason
Wells Fargo upgraded AptarGroup to Overweight from Equal Weight with a price target of $144, up from $133. The firm says the share price reaction relating to the Iran conflict has been "disproportionate" across the packaging sector. Wells prefers companies with low leverage, high U.S concentration, and "defensive" production exposures. The analyst adjusted ratings in the group. AptarGroup offers a "best-in-class" balance sheet and heavy exposure to the "defensive" pharma sector, which is key during periods of uncertainty, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ATR
Unlock Now

Valuation Metrics

The current forward P/E ratio for Aptargroup Inc (ATR.N) is 24.10, compared to its 5-year average forward P/E of 27.03. For a more detailed relative valuation and DCF analysis to assess Aptargroup Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
27.03
Current PE
24.10
Overvalued PE
30.42
Undervalued PE
23.63

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
13.16
Current EV/EBITDA
12.28
Overvalued EV/EBITDA
14.44
Undervalued EV/EBITDA
11.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.41
Current PS
1.96
Overvalued PS
2.73
Undervalued PS
2.09

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

which stocks are recommended to buy today?
Intellectia · 86 candidates
Market Cap: >= 5.00BAnalyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Week Predict Return: >= 4.0%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
CPAY logo
CPAY
Corpay Inc
23.58B
AKAM logo
AKAM
Akamai Technologies Inc
16.08B
MLM logo
MLM
Martin Marietta Materials Inc
40.94B
VMC logo
VMC
Vulcan Materials Co
43.29B
EAT logo
EAT
Brinker International Inc
7.01B
PM logo
PM
Philip Morris International Inc
291.89B
best earrings stock for tomorrow
Intellectia · 9 candidates
Market Cap: >= 1000.00MAnalyst Consensus: Strong Buy, Moderate BuyWeekly Average Turnover: >= 1,000,000Pe Ttm: <= 25Earnings Surprise: EpsBeatAnnual Eps Yoy Growth: >= 20.0%
Ticker
Name
Market Cap$
top bottom
TMUS logo
TMUS
T-Mobile US Inc
205.36B
SUI logo
SUI
Sun Communities Inc
15.43B
AVY logo
AVY
Avery Dennison Corp
14.37B
UHS logo
UHS
Universal Health Services Inc
12.73B
FLS logo
FLS
Flowserve Corp
9.85B
ATR logo
ATR
Aptargroup Inc
8.20B

Whales Holding ATR

C
Crawford Investment Counsel, Inc.
Holding
ATR
+1.87%
3M Return
A
Aristotle Capital Boston, LLC
Holding
ATR
+0.79%
3M Return
F
Fiduciary Management, Inc.
Holding
ATR
+0.16%
3M Return
A
ATB Investment Management Inc.
Holding
ATR
-1.44%
3M Return
R
River Road Asset Management, LLC
Holding
ATR
-2.03%
3M Return
S
Schwartz Investment Counsel, Inc.
Holding
ATR
-2.59%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Aptargroup Inc (ATR) stock price today?

The current price of ATR is 125.39 USD — it has decreased -0.49

What is Aptargroup Inc (ATR)'s business?

AptarGroup, Inc. is engaged in designing and manufacturing of drug and consumer product dosing, dispensing and protection technologies. The Company serves various end markets, including pharmaceutical, beauty, food, beverage, personal care and home care. It operates in three segments. The Aptar Pharma segment sells proprietary dispensing systems, drug delivery systems, sealing solutions and services for the prescription drug, consumer health care, injectables, active material science solutions and digital health market. It also specializes in nasal drug delivery for delivering drugs. The Aptar Beauty segment sells dispensing systems and sealing solutions for the beauty, personal care and home care markets. The Aptar Closures segment sells dispensing systems, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and healthcare markets. This segment also includes the food protection business and the elastomeric flow-control technology business.

What is the price predicton of ATR Stock?

Wall Street analysts forecast ATR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATR is145.33 USD with a low forecast of 133.00 USD and a high forecast of 156.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Aptargroup Inc (ATR)'s revenue for the last quarter?

Aptargroup Inc revenue for the last quarter amounts to 962.74M USD, increased 13.52

What is Aptargroup Inc (ATR)'s earnings per share (EPS) for the last quarter?

Aptargroup Inc. EPS for the last quarter amounts to 1.13 USD, decreased -23.65

How many employees does Aptargroup Inc (ATR). have?

Aptargroup Inc (ATR) has 14000 emplpoyees as of April 06 2026.

What is Aptargroup Inc (ATR) market cap?

Today ATR has the market capitalization of 8.04B USD.